TET2 mutations are associated with CN-AML or intermediate-risk cytogenetic abnormalities and with increased age, higher WBC and blast counts, low platelet count and FLT3-ITD, NPM1 and ASXL1 mutations, but are mutually exclusive with IDH1 and IDH2 mutations [7,53]. This evidence concerns the gene FLT3 and acute myeloid leukemia.